Page last updated: 2024-11-04

aconitic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

trans-aconitic acid : The trans-isomer of aconitic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

cis-aconitic acid : The cis-isomer of aconitic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Aconitic Acid: A tricarboxylic acid with the formula (COOH)-CH2-C(COOH)=CH-COOH. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

aconitic acid : A tricarboxylic acid that is prop-1-ene substituted by carboxy groups at positions 1, 2 and 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID444212
CHEMBL ID153658
CHEBI ID32806
SCHEMBL ID219037
MeSH IDM0000235
PubMed CID643757
CHEMBL ID347285
CHEBI ID32805
SCHEMBL ID16935
MeSH IDM0000235
PubMed CID309
CHEBI ID22211
MeSH IDM0000235

Synonyms (199)

Synonym
aconitate
bdbm50036212
1-propene-1,2,3-tricarboxylic acid, (e)-
nsc 43980
7db37960cw ,
einecs 223-688-6
aconitic acid, (e)-
1-propene-1,2,3-tricarboxylic acid, (1e)-
1-propene-1,trans-2,3-tricarboxylic acid
unii-7db37960cw
1-propene-1,3-tricarboxylic acid
nsc-7616
(1e)-prop-1-ene-1,2,3-tricarboxylic acid
(1e)-1-propene-1,2,3-tricarboxylic acid
CHEBI:32806 ,
(e)-1-propene-1,2,3-tricarboxylic acid
BSPBIO_003135
1-propene-1,3-tricarboxylic acid, (e)-
aconitic acid, trans
nsc-43980
NSC43980 ,
SDCCGMLS-0066594.P001
(e)-prop-1-ene-1,2,3-tricarboxylic acid
NCGC00013082
SPECTRUM5_000568
TRA ,
C02341
trans-aconitic acid
4023-65-8
trans-aconitic acid, >=98%, fcc
trans-aconitic acid, 98%
NCGC00095868-01
SPECTRUM310001
NCGC00095868-02
A-2400
3E5FE8F1-643F-407E-841A-8FF4E837F331
aconitic acid, trans-
A0127
CHEMBL153658 ,
AKOS000490916
NCGC00182966-01
dtxsid1048706 ,
cas-4023-65-8
tox21_113103
dtxcid8028632
A824996
CCG-38436
NCGC00013082-02
NCGC00013082-03
S3090
trans-propene-1,2,3-tricarboxylic acid
fema no. 2010, e-
SCHEMBL219037
NCGC00013082-04
tox21_113103_1
transaconitic acid
trans aconitic acid
(e)-aconitic acid
mfcd00002721
AC-10006
SR-05000002405-1
sr-05000002405
(1e)1-propene-1,2,3-tricarboxylic acid
1-propene-1-trans-2,3-tricarboxylic acid
(1e)1-propene-1,2,3-tricarboxylate
trans-1-propene-1,2,3-tricarboxylic acid
1-trans-propene-1,2,3-tricarboxylic acid
(1e)-prop-1-ene-1,2,3-tricarboxylic
CS-W017529
HY-W016813
Q27104227
STR02775
D78372
trans-aconitic acid 1-propene-1,2,3-tricarboxylic acid
(e)-prop-1-ene-1,2,3-tricarboxylicacid
EN300-7397726
trans-aconitic acid;1-propene-1,2,3-tricarboxylic acid
unii-93371t1bxp
93371t1bxp ,
bdbm50036222
EN300-18352
glutaconic acid, 3-carboxy-
achilleaic acid
pyrocitric acid
citridic acid
citridinic acid
equisetic acid
achilleic acid
wln: qv1yvqu1vq
2-pentenedioic acid, 3-carboxy-
CHEBI:32805 ,
(z)-1-propene-1,2,3-tricarboxylic acid
(1z)-prop-1-ene-1,2,3-tricarboxylic acid
cis-1-propene-1,2,3-tricarboxylic acid
cis-aconic acid
1,3-propenetricarboxylic acid
nsc-227901
1-propene-1,3-tricarboxylic acid, cis-
1-propene-1,3-tricarboxylic acid, (z)-
nsc227901
cis-oxaloacetic acid
ai3-14615
ccris 2507
3-carboxyglutaconic acid
hsdb 635
1,2,3-propenetricarboxylic acid
fema no. 2010
nsc 7616
einecs 207-877-0
C16034
1,2,3-propenetricarboxylic acid,(trans)
inchi=1/c6h6o6/c7-4(8)1-3(6(11)12)2-5(9)10/h1h,2h2,(h,7,8)(h,9,10)(h,11,12)/b3-1
prop-1-ene-1,2,3-tricarboxylic acid
585-84-2
cis-aconitic acid
C00417
CIS-ACONITATE ,
NCI7616
cis-aconitic acid, >=98%
STK077565
70398F21-6D08-4F6F-8E72-7AD7EFC52A8B
CHEMBL347285 ,
(z)-prop-1-ene-1,2,3-tricarboxylic acid
BMSE000705
cis-propene-1,2,3-tricarboxylic acid
AKOS001426595
BBL012090
CCG-37620
1,cis-2,3-propenetricarboxylic acid
1-propene-1,2,3-tricarboxylic acid, (z)-
of5471zhrr ,
1-propene-1,2,3-tricarboxylic acid, (1z)-
aconitic acid, (z)-
einecs 209-564-4
nsc 227901
aconitic acid, cis-
cis-aconitum acid
1-propene-1,2,3-tricarboxylic acid, cis-
unii-of5471zhrr
fema no. 2010, z-
S4939
AB01333406-02
SCHEMBL16935
1-propene-1,2,3-tricarboxylic acid, trans
GTZCVFVGUGFEME-IWQZZHSRSA-N
(z)-aconitic acid
hydrogen cis-aconitate
Z57204893
1-cis-2,3-propenetricarboxylate
(1z)-1-propene-1,2,3-tricarboxylate
cis-1-propene-1,2,3-tricarboxylate
(z)-1-propene-1,2,3-tricarboxylate
1-cis-2,3-propenetricarboxylic acid
(1z)-1-propene-1,2,3-tricarboxylic acid
cis-aconate
cis-oxaloacetate
1-propene-1,2,3-tricarboxylate
(z)-aconitate
NCGC00182966-03
Q27104226
cis-aconitic-acid
propene-1,2,3-tricarboxylicacid
1-propene-cis(1,2),3-tricarboxylic acid
DTXSID30883449
cls-aconitic acid
(1z)-propene-1,2,3-tricarboxylic acid
z-aconitic acid
AS-81537
nsc7616 ,
499-12-7
aconitic acid
KBIO1_001419
DIVK1C_006475
NCI60_041679
SPECTRUM_001377
SPECTRUM4_001744
propene-1,2,3-tricarboxylic acid
CHEBI:22211
3-carboxy-2-pentenedioic acid
1-propene-1,2,3-tricarboxylic acid
KBIO2_001857
KBIOSS_001857
KBIO2_004425
KBIOGR_002188
KBIO3_002355
KBIO2_006993
NCISTRUC1_000121
SPECPLUS_000379
NCISTRUC2_000171
SPECTRUM3_001348
SPECTRUM2_001788
SPBIO_001715
FT-0659941
FT-0623933
DTXSID9060102
AKOS028109456
GTZCVFVGUGFEME-UHFFFAOYSA-N
disperseviolet26
Q288782

Research Excerpts

Overview

Aconitic acid is an unsaturated tricarboxylic acid. It is attractive for its potential use in manufacturing biodegradable and biocompatible polymers, plasticizers, and surfactants.

ExcerptReferenceRelevance
"Aconitic acid is an unsaturated tricarboxylic acid that is attractive for its potential use in manufacturing biodegradable and biocompatible polymers, plasticizers, and surfactants. "( Identification of a specific exporter that enables high production of aconitic acid in Aspergillus pseudoterreus.
Burnum-Johnson, KE; Dai, Z; Deng, S; Duong, RD; Evans, JE; Gao, Y; Hofstad, BA; Kim, J; Kim, YM; Lemmon, T; Magnuson, J; Munoz, N; Nicora, C; Novikova, IV; Pomraning, KR; Powell, SM; Robles, AL; Swita, M; Webb-Robertson, BJ, 2023
)
2.59

Effects

ExcerptReferenceRelevance
"Aconitic acid (AA) has been identified in those plants in high concentration."( Allelopathic effects of aconitic acid on wild poinsettia (Euphorbia heterophylla) and morningglory (Ipomoea grandifolia).
Filho, RV; Voll, CE; Voll, E, 2005
)
1.36

Pharmacokinetics

ExcerptReferenceRelevance
" The present pharmacokinetic and toxicologic data of Suc-HSA and Aco-HSA show that both compounds are interesting preparations for studies in SIV infected monkeys and AIDS patients."( Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA.
Beljaars, E; Meijer, DK; Pasma, A; Schuitemaker, H; Smit, C; Swart, PJ, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The fumaric acid based dry granulated product demonstrated a mean bioavailability comparable to an oral solution dose in a dog model."( Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound.
Dalziel, SM; Menning, MM, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fundamental metaboliteAny metabolite produced by all living cells.
fundamental metaboliteAny metabolite produced by all living cells.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aconitic acidA tricarboxylic acid that is prop-1-ene substituted by carboxy groups at positions 1, 2 and 3.
aconitic acidA tricarboxylic acid that is prop-1-ene substituted by carboxy groups at positions 1, 2 and 3.
tricarboxylic acidAn oxoacid containing three carboxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (40)

PathwayProteinsCompounds
Secondary Metabolites: Glyoxylate Cycle715
Citric Acid Cycle2127
Congenital Lactic Acidosis2127
Fumarase Deficiency2127
Mitochondrial Complex II Deficiency2127
2-Ketoglutarate Dehydrogenase Complex Deficiency2127
Pyruvate Dehydrogenase Deficiency (E3)2127
Pyruvate Dehydrogenase Deficiency (E2)2127
TCA Cycle1825
TCA cycle (ubiquinol-2)1824
TCA cycle (ubiquinol-3)1823
TCA cycle (ubiquinol-4)1824
TCA cycle (ubiquinol-5)1823
TCA cycle (ubiquinol-6)1825
TCA cycle (ubiquinol-7)1825
TCA cycle (ubiquinol-8)1825
TCA cycle (ubiquinol-9)1823
TCA cycle (ubiquinol-10)1824
Glycolate and Glyoxylate Degradation II1221
TCA cycle (ubiquinol-0)1825
The Oncogenic Action of 2-Hydroxyglutarate2734
The Oncogenic Action of Succinate2933
The Oncogenic Action of Fumarate2934
Glutaminolysis and Cancer3536
Glyoxylate Cycle613
The Oncogenic Action of L-2-Hydroxyglutarate in Hydroxyglutaric aciduria2835
The Oncogenic Action of D-2-Hydroxyglutarate in Hydroxyglutaric aciduria2936
Glutamine Metabolism2225
Citrate cycle ( Citrate cycle )2129
Citric acid = Isocitric acid ( Citrate cycle )24
Citric acid = cis-Aconitic acid + H2O ( Citrate cycle )23
Amino acid metabolism pathway excerpt: histidine catabolism extension016
Citrate Cycle1930
TCA Cycle (Ubiquinol-2)424
TCA Cycle (Ubiquinol-3)423
TCA Cycle (Ubiquinol-4)424
TCA Cycle (Ubiquinol-5)423
TCA Cycle (Ubiquinol-6)425
TCA Cycle (Ubiquinol-7)425
TCA Cycle (Ubiquinol-8)425
TCA Cycle (Ubiquinol-9)423
TCA Cycle (Ubiquinol-10)424
TCA Cycle (Ubiquinol-0)425
TCA cycle, aerobic respiration020
Primary carbon metabolism2330
Krebs cycle110
AtMetExpress overview0109
Biochemical pathways: part I0466
Amino acid metabolism094
TCA cycle (aka Krebs or citric acid cycle)024

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency12.55940.140911.194039.8107AID2451
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
GLI family zinc finger 3Homo sapiens (human)Potency4.73080.000714.592883.7951AID1259369
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
cytochrome P450 2D6Homo sapiens (human)Potency38.90180.00108.379861.1304AID1645840
Cellular tumor antigen p53Homo sapiens (human)Potency0.26600.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-citrate synthase Rattus norvegicus (Norway rat)Ki1,000.00000.15004.75718.0000AID32395
ATP-citrate synthase Rattus norvegicus (Norway rat)Ki1,000.00000.15004.75718.0000AID32395
Prolyl 4-hydroxylaseParamecium bursaria Chlorella virus 1IC50 (µMol)1,000.00005.00006.26678.5000AID1543452
Alpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)IC50 (µMol)1,000.00003.00006.10009.8000AID734755
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (135)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
temperature homeostasisAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
DNA alkylation repairAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of lipid storageAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
snRNA processingAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of multicellular organism growthAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
RNA repairAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of respiratory system processAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
adipose tissue developmentAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
mRNA destabilizationAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of white fat cell proliferationAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
regulation of brown fat cell differentiationAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (40)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
ferrous iron bindingAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
transferase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
oxidative RNA demethylase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
broad specificity oxidative DNA demethylase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
mRNA N6-methyladenosine dioxygenase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
tRNA demethylase activityAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleusAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
nucleoplasmAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
cytoplasmAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
cytosolAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
plasma membraneAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
nuclear speckAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-ketoglutarate-dependent dioxygenase FTOHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1432751Inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production using urea as substrate measured for 120 mins by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1432754Time-dependent Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production using urea as substrate by phenol-hypochlorite method2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1432755Competitive inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production preincubated with enzyme followed by addition of varying levels of urea as substrate measured for 120 mins by Lineweaver-Burk plot analysis2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID32395Reversible binding potential for rat ATP-Citrate Lyase as carbon-carbon bond cleavage activity in citrate substrate1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Synthesis of novel thiol-containing citric acid analogues. Kinetic evaluation of these and other potential active-site-directed and mechanism-based inhibitors of ATP citrate lyase.
AID1432756Reversible inhibition of Sporosarcina pasteurii CCM 2056 urease assessed as reduction in ammonia production by measuring recovery of enzyme activity at 10 times IC50 preincubated for 60 mins followed by 100-fold dilution in to PBS containing urea as subst2017Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6
Potent covalent inhibitors of bacterial urease identified by activity-reactivity profiling.
AID1685613Covalent inhibition of wild type N-terminal polyhis-tagged TEV protease cleavage site fused Mycobacterium tuberculosis ICL1 expressed in Escherichia coli BL21 (DE3) using DL-isocitrate as substrate measured after 1 hr by UV-Vis spectrophotometric analysis2021RSC medicinal chemistry, Jan-01, Volume: 12, Issue:1
Itaconate is a covalent inhibitor of the
AID32394Irreversible inactivation of rat ATP-Citrate Lyase; nd=not detectable1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Synthesis of novel thiol-containing citric acid analogues. Kinetic evaluation of these and other potential active-site-directed and mechanism-based inhibitors of ATP citrate lyase.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1543452Inhibition of N-terminal His6-tagged recombinant Paramecium bursaria chlorella virus 1 CPH expressed in Escherichia coli Rosetta 2 (DE3) cells pre-incubated for 5 mins before 2OG as substrate and Fe2 as co-factor addition in presence of L-ascorbate and me2019Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12
Inhibition of a viral prolyl hydroxylase.
AID32394Irreversible inactivation of rat ATP-Citrate Lyase; nd=not detectable1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Synthesis of novel thiol-containing citric acid analogues. Kinetic evaluation of these and other potential active-site-directed and mechanism-based inhibitors of ATP citrate lyase.
AID32395Reversible binding potential for rat ATP-Citrate Lyase as carbon-carbon bond cleavage activity in citrate substrate1995Journal of medicinal chemistry, Feb-03, Volume: 38, Issue:3
Synthesis of novel thiol-containing citric acid analogues. Kinetic evaluation of these and other potential active-site-directed and mechanism-based inhibitors of ATP citrate lyase.
AID1685613Covalent inhibition of wild type N-terminal polyhis-tagged TEV protease cleavage site fused Mycobacterium tuberculosis ICL1 expressed in Escherichia coli BL21 (DE3) using DL-isocitrate as substrate measured after 1 hr by UV-Vis spectrophotometric analysis2021RSC medicinal chemistry, Jan-01, Volume: 12, Issue:1
Itaconate is a covalent inhibitor of the
AID734755Inhibition of human hexahistidine-tagged full-length FTO expressed in Escherichia coli BL21 (DE3) using 3-methylthymidine as substrate assessed as inhibition of 3-methylthymidine conversion to thymidine after 1 hr by liquid chromatographic analysis2013Journal of medicinal chemistry, May-09, Volume: 56, Issue:9
Structural basis for inhibition of the fat mass and obesity associated protein (FTO).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (215)

TimeframeStudies, This Drug (%)All Drugs %
pre-199066 (30.70)18.7374
1990's30 (13.95)18.2507
2000's26 (12.09)29.6817
2010's62 (28.84)24.3611
2020's31 (14.42)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 84.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index84.82 (24.57)
Research Supply Index5.34 (2.92)
Research Growth Index4.72 (4.65)
Search Engine Demand Index149.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (84.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (16.67%)6.00%
Reviews2 (0.96%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
Other5 (83.33%)84.16%
Other206 (99.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]